The extent to which gene fusions function as drivers of cancer remains a critical open question 16 in cancer biology. In principle, transcriptome sequencing provided by The Cancer Genome 17 Atlas (TCGA) enables unbiased discovery of gene fusions and post-analysis that informs the 18 answer to this question. To date, such an analysis has been impossible because of 19 performance limitations in fusion detection algorithms. By engineering a new, more precise, 20 algorithm and statistical approaches to post-analysis of fusions called in TCGA data, we report 21 new recurrent gene fusions, including those that could be druggable; new candidate pan-cancer 22 oncogenes based on their profiles in fusions; and prevalent, previously overlooked, candidate 23 oncogenic gene fusions in ovarian cancer, a disease with minimal treatment advances in recent 24 decades. The novel and reproducible statistical algorithms and, more importantly, the biological 25 conclusions open the door for increased attention to gene fusions as drivers of cancer and for 26 future research into using fusions for targeted therapy. 27 28 Thus, the critical question, "are gene fusions under-appreciated drivers of cancer?", is 59 still unanswered. In this paper, we provide several contributions that more precisely define and 60 provide important advances to answering this question. First, we provide a new algorithm that 61 has significant improvements in precision for unbiased fusion detection in massive genomics 62 datasets. Our new algorithm, sMACHETE (scalable MACHETE), significantly builds on our 63 recently developed MACHETE algorithm (Hsieh et al., 2017) to discover new gene fusions and 64 pan-cancer signatures of selection. Its algorithmic advance over MACHETE is to use novel 65 modeling to account for challenges brought on by "big data": statistical modeling to identify false 66 positives and avoid heuristic or human-guided filters that are commonly imposed by other fusion 67 detection algorithms. We have systematically evaluated sMACHETE's false positive rate, which 68 is much lower than other algorithms, and show that sMACHETE has sensitive detection of gold 69
Introduction 29
While genomic instability is a hallmark of human cancers, its functions have only partially 30 been explained. Point mutations and gene dosage effects result from genomic instability, but 31 they alone do not explain the origin of human cancers (Martincorena et al., 2015) . Genomic 32 instability also results in structural variation in DNA that creates rearrangements, including local 33 duplications, deletions, inversions or larger scale intra-or inter-chromosomal rearrangements 34 that can be processed into mRNAs that are gene fusions. 35
Gene fusions are known to drive some cancers and can be highly specific and 36 personalized therapeutic targets; among the most famous are the BCR-ABL1 fusion in chronic 37 myelogenous leukemia (CML), and the EML4-ALK fusion in non-small lung cell carcinoma 38 (Soda et al., 2007; Nowell and Hungerford, 1960) . Fusions are among the most clinically 39 relevant events in cancer because of their use to direct targeted therapy and because of early 40 detection strategies using RNA or proteins; moreover, as they are truly specific to cancer, they 41 have promising potential as neo-antigens (Zhang, Mardis and Maher, 2017 ; Ragonnaud and 42 Holst, 2013; Liu and Mardis, 2017) . 43
Because of this, major efforts by clinicians and large sequencing consortia attempt to 44 identify fusions expressed in tumors. However, these attempts are limited by critical roadblocks: 45 current algorithms suffer from high false positive rates and unknown false negative rates. Thus, 46 heuristic approaches and filters are imposed, including taking the consensus of multiple 47 algorithms or imposing priority on the basis of gene ontologies given to fusion partners. These 48 approaches lead to what third party reviews agree is imprecise fusion discovery and bias 49 against discovering novel oncogenes (Liu et al., 2015; Carrara et al., 2013; Kumar et al., 2016) . 50
Both shortcomings in ascertainment of fusions by existing algorithms and using recurrence 51 alone to assess function limit the use of fusions to discover new cancer biology. As one of many 52 examples, a recent study of more than 400 pancreatic cancers found no recurrent gene fusions, 53 raising the question if this is due to high false negative rates or this means that fusions are not 54 drivers in the disease (Bailey et al., 2016) . Recurrence of fusions is currently one of the only 55 standards in the field used to assess functionality of fusions, but the most frequently expressed 56 fusions may not be the most carcinogenic (Saramäki et al., 2008) ; on the other hand, there may 57 still be many undiscovered gene fusions that drive cancer. 58 standard positive controls. Beyond recovery of known fusions, sMACHETE predicts novel 70 fusions, the focus of this paper. These fusions include recurrent fusions, two of which we 71 validate in independent samples, and recurrent 5' and 3' partner genes. 72
The improved precision of sMACHETE has allowed us to address several unresolved 73 questions in cancer biology. First, until now, a large fraction of ovarian cancers have lacked 74 explanatory drivers beyond nearly universal TP53 mutations and defects in homologous 75 recombination pathways. Because TP53 mutations create genome instability, a testable 76 hypothesis is that TP53 mutations permit the development of rare or private driver fusions in 77 ovarian cancers, and the fusions have been missed due to biases in currently available 78 algorithms. We apply sMACHETE to RNA-Seq data from bulk tumors and find that 91% of the 79 ovarian tumors we screened have detectable fusions and that 54% of the ovarian cancer tumors 80 express gene fusions involving kinase pathways or known Catalogue of Somatic Mutations In 81 Cancer (COSMIC) genes (Forbes et al., 2014) . We also identify novel although low-prevalence 82 recurrent fusions in other cancers, including pancreatic cancer, where they have not been 83 described previously. 84
Frequent recurrence of gene fusions is a hallmark of a selective event during tumor 85 initiation, and this recurrence has historically been the only evidence available to support that a 86 fusion drives a cancer. While private or very rare gene fusions are beginning to be considered 87 as potential functional drivers (Latysheva and Babu, 2016) , the high false positive rates in 88 published algorithms prevent a statistical analysis of whether private or rare gene fusions 89 reported exhibit a signature of selection across massive tumor transcriptome databases, such 90 as TCGA. Signatures of selective advantage of fusion expression include recurrent use of a 5' 91 or 3' partner, or enrichment of gene families such as those in Catalogue Of Somatic Mutations 92
In Cancer (COSMIC). We formulate and provide the first such analysis. 93
In sum, sMACHETE is an advance in accuracy for fusion detection in massive RNA- 2017), which reports significantly more fusions in cancer samples that are also detected in 155 normals, suggesting they are false positives ( Fig. 4) . We have used fusions called by 156
ChimerSeq to compare sMACHETE's sensitivity and specificity because ChimerSeq entails 157 performance benchmarking of multiple 'top performing' algorithms, and, using a disciplined 158 procedure for evaluating them, instantiates a meta-caller to produce more reliable calls than any 159 algorithm independently (Lee et al., 2017) . 160
Any algorithm's FPR can be trivially reduced by sacrificing sensitivity. However, we find 161 that sMACHETE's precision may in fact improve sensitivity. In primary tumors, no ground truth 162 is known, so we use well-studied and generally cytogenetically simple tumor types such as 163 acute myeloid leukemia (LAML) as a best approximation. In a large cohort of LAML samples 164 investigated through both next-generation sequencing and cytogenetics by a large consortium 165 Table 1 ). While generally low prevalence, several novel fusions were 208 detected at sufficient frequency that they would be expected to appear in an independent, 209 moderate number of primary tumor samples that our laboratory could reasonably test. 210
Using sMACHETE's predictions from TCGA data, we attempted to validate four novel 211 and one previously reported recurrent fusions on nine primary ovarian tumor samples, labeled 212 (A-I). We first tested for two novel fusions: CPSF6-CHMP1A, a fusion consistent with deriving 213 from interchromosomal rearrangement, and RB1-ITM2B, a rearrangement between two 214 neighboring genes. Samples (C,E,F) (33%) had PCR products of the expected size for CPSF6-215 While we did not attempt to distinguish whether an underlying DNA change was responsible for 221 the RB1-ITM2B fusion, the estimated prevalence of RB1-ITM2B from poly(A) selected TCGA 222 libraries was only 2%. This is much lower than the 55% prevalence detected by PCR, and is 223 consistent with the hypothesis that RB1-ITM2B is a circRNA that is depleted in poly(A) selected 224
libraries. 225
We tested the same samples for three other fusions detected by sMACHETE: a 226 previously known germline fusion, TFG-GPR128 (Chase et al., 2010) and two predicted 227 ovarian-specific recurrent fusions, METTL3-TM4SF1 and RCC1-UBE2D2. Consistent with the 228 range of previous reports of the prevalence of TFG-GPR128 in the population (3/120 as 229 reported in Chase et al., 2010, 95% CI: 0.5%-7.1%), sMACHETE estimates its frequency in 230 TCGA data to be <1% in sarcoma (SARC), 2.2% in PAAD, and 1.4% in ovarian serous 231 cystadenocarcinoma (OV) (see Supplemental Table 1 ). The predicted frequency of METTL3-232 TM4SF1 and RCC1-UBE2D2 were similarly low (5.9% and 3.8% of OV cases, respectively). All 233 samples tested by PCR for these three fusions were negative, which is consistent with their 234 estimated prevalence under a simple binomial sampling model. Because of the low prevalence, 235 a much larger sample size, greater than one hundred, would be necessary to provide sufficient 236 statistical power to test if these fusions are recurrent. 237
Fusions identified by sMACHETE are enriched in known oncogenes 239
Because we, and the vast majority of researchers, do not have access to TCGA samples 240 for additional PCR validation, we used orthogonal computational tests of sMACHETE's novel 241 fusion predictions to support the assertion that most of sMACHETE's fusion predictions are not 242 artifacts. We first investigated the distribution of functional gene ontologies of reported fusion 243 partners, as these are not used by sMACHETE and so provide an independent test of whether 244 sMACHETE is identifying a potentially important biological signal. To test whether the putative 245 fusions identified by sMACHETE are enriched for genes in known cancer pathways, for each The most common genetic lesion in ovarian cancer is the TP53 mutation, present in 88% 260 of cases (cBioPortal, retrieved July 18, 2017, see Gao et al., 2013) , although there is debate in 261 the literature that this prevalence is an underestimate. Regardless, other drivers must exist 262 because, for example, TP53 mutations are not sufficient to cause cancers (Martincorena et al., 263 2015) . In OV, such explanatory driving events are as yet unknown (Bowtell et al., 2015). The 264 prevalence of TP53 mutations generates the hypothesis that the resulting genome instability 265 could generate fusions responsible for driving some fraction of these cancers, but which have 266 been missed because of shortcomings in other available algorithms; we sought to test this 267 hypothesis. 268 sMACHETE reports 91% of all ovarian cancers in its discovery set to have a gene 269 fusion, the highest rate of any disease we profiled. 54% of ovarian tumors contain a fusion 270 involving a kinase or COSMIC gene, a higher frequency than any other profiled disease (see 271 Table 1 ). This fusion is 275 also reported in LAML by a separate group, and is consistent with the fusion being a circular 276 RNA (Cancer Genome Atlas Research Network, 2013). 277 Recurrent fusions of low prevalence involving genes on different chromosomes, unlikely 278 to be circRNA, were detected as described above: 3.8% of tumors were estimated to have the 279 fusion RCC1-UBE2D2. RCC1 is a regulator of chromosome condensation and UBE2D2 is an 280 ubiquitin conjugating enzyme. RCC1-UBE2D2 is predicted to be specific to ovarian tumors. The 281 fusion METTL3-TM4SF1 of METTL3, a methyltransferase-like protein involved in splicing, and 282 TM4SF1, a transmembrane protein of unknown function, was seen in 5.9% of tumors and also 283 specific to ovarian cancer. 284 sMACHETE predicts that the rate that fusions are present in ovarian cancer is higher Further, our discovery of a high fraction of gene fusions in ovarian cancer is consistent 294 with an orthogonal metric of genome instability in this disease, its TP53 mutation rate of 88% 295 (Methods; TCGA, 2011). This, along with sMACHETE's specificity on normal controls, supports 296 the interpretation that fusions, perhaps relatively rare or private events, could be an 297 unappreciated driver of ovarian cancers (see Fig. 5 ). Functional tests of this hypothesis are 298 important but beyond the scope of this paper, and there is an important clinical implication that if 299 rare or low prevalence fusions are common, and if some are potentially druggable, then 300 'personalized' tumor profiling would be needed to inform treatment. 301 302
Statistical analysis of private fusions predicts new oncogenes 303
Fusions that recur with relatively high frequencies across cases are appreciated to have 304 a selective advantage for tumors, because recurrence has historically been used as a proxy for 305 function in cancer biology. However, statistical signals in rare fusions, including private fusions 306 that are observed only once, could still have statistical features that distinguish them from 307 molecular events deemed 'passengers'. While intuition for this idea has been appreciated ( the 660 reported earlier regarding fusions called by ChimerSeq.) We tested whether the 5' or 3' 319 partners reappeared on the list of private fusions more often than would be expected compared 320 to a null distribution using a statistical model that is a generalization of the well-known "birthday 321 problem" (Henze, 1998, Supplemental File) . We omitted recurrent fusions in the analysis of 322 enrichment for 5' and 3' partners as a conservative measure to prevent a bias for re-discovering 323 known oncogenic fusions and enriching a statistical signal, because many gene fusions that are 324 recurrent have had functional assignments as oncogenes because there is bias towards 325 studying them. 326
This analysis establishes both the excess or 'effect size' for the number of genes 327 recurrently present in a 5' and 3' fusion and statistical significance (Supplemental File). 328 sMACHETE reports 38 recurrent 5' partners and 33 recurrent 3' partners, with both having 329 corresponding p-values << 10 -5 , which are highly statistically significant findings. Moreover, this 330 is a finding with a large effect size: sMACHETE predicts tens of novel oncogenic fusion partners 331 from this analysis, which is based on profiling completely private gene fusions; deeper 332 sequencing or larger sample sizes and more cases or cancer types could further increase this 333 number. 334
In principle, any gene fusion, including recurrent gene fusions, may be expressed due to 335 a predisposition for genomic rearrangement between two loci rather than RNA expression 336 conferring a particular advantage to the tumor. Thus, in addition to the above statistical 337 evidence, we investigated the gene ontology of genes with multiple partners using the logic that 338 gene fusions can activate oncogenes through a variety of mechanisms, for example those that 339 result in omission of a functional domain through truncation (Shirole et al., 2016) that could have 340 similar effects to point mutations. If our analysis is identifying a real signal, we expect some 341 known oncogenes should be reidentified and enriched as gene partners identified in the above 342
analysis. 343
We find that known oncogenes are amongst the most significantly enriched 5' and 3' 344 partners in private gene fusions. For example, RALA, a Ras-family G-protein and known 345 oncogene (Lim et al., 2005) , has three distinct partners found in OV and GBM; to our knowledge 346 it has not been previously reported as a recurrent fusion partner, a feature suggesting that it 347 functions as an oncogene through gene fusion. A fourth fusion involving RALA, RALA-YAE1D1, 348 was identified by sMACHETE as a recurrent gene fusion in OV (see Supplemental Table 1 ), and 349 hence did not contribute to RALA's score by this method. ZBTB20, a known oncogene (Lim et These examples raise the possibility that within a single cancer type (in the above 366 example, LAML or pancreatic neuroendocrine tumors) low-prevalence recurrent gene fusions 367 could be drivers of these specific tumor cases above, and more generally that recurrent fusions 368 that are rare within a tumor type could drive some cancers. In this scenario, either very high 369 sample sizes or pan-cancer analysis would be necessary to detect them. Further, if some of 370 these fusions were recurrent across a pan-cancer panel, but had low overall prevalence, 371 surveys of the TCGA datasets by consortia studying a single tumor may have missed them 372 because such analysis typically involves profiling only one disease. We sought to test if, like 373 private fusions, sMACHETE identified rare recurrent fusions that were observed at rate higher 374 than expected by chance and that would be consistent with being under selection 375 (Supplemental File) . 376 sMACHETE predicted 100 recurrent gene fusions, indeed far more than would be 377 expected by chance (Supplemental File). This list includes fusions detected in more than one 378 cancer and those that involve partners with annotations indicating potential druggability, such as 379 kinases, chromatin remodeling complexes, and other signaling molecules (e.g., Strawberry 380
Notched Homolog, SBNO2, in the putative fusion product SBNO2-SERINC2; Supplemental 381 Table 1 ). Another example is a fusion involving the ribosomal protein kinase RPS6KB1-VMP1, 382 previously identified as a recurrent fusion in breast invasive carcinoma (BRCA) (Inaki, et al., 383 2011) , which was detected for the first time in other cancer types, such as lung adenocarcinoma 384 (LUAD) and OV (Supplemental Table 1 ). PAAD, which had previously lacked reports of 385 recurrent fusions, was found to harbor a group of low-prevalence recurrent fusions when all 386 cancer types were used to estimate recurrence. Some of these rare recurrent gene fusions were 387 present across tumor types in addition to PAAD; for example, ERBB2-PPP1R1B was detected 388 in two total tumors across TCGA including once in PAAD. The examples above represent 389 fusions that in principle, could conceivably be targetable with current drugs ( Supplemental Table  390 1), pending further tests. They show the potential for fusions, and not just point mutations, to 391 stratify patients clinically. 392 393 Discussion 394 Some of the first oncogenes were discovered with statistical modeling that linked 395 inherited mutations and cancer risk (e.g. Knudson, 1971 ). The advent of high-throughput 396 sequencing has promised the discovery of novel oncogenes which can inform basic biology and 397 provide therapeutic targets or biomarkers (Cibulskis et al., 2013; Lawrence et al., 2014). 398 However, unbiased, sequencing-based, methodologies for discovery of novel oncogenic 399 gene fusions have been only partially successful. Many likely driving, and druggable, gene 400 fusions have been identified by high-throughput sequencing, but studies reporting them have a 401 non-tested or non-trivial false positive rate even using heuristic or ontological filters, making 402 them unreliable for clinical use. These problems also limit their sensitivity in unbiased screens of 403 massive data sets to discover fusions, novel oncogenes or signatures of evolutionary advantage 404 for rare or private gene fusions. 405
In this paper, we present sMACHETE, a unified, reproducible statistical algorithm to 406 detect gene fusions in RNA-Seq data set without human-guided filtering. sMACHETE has 407 significantly lower false positive rates than other algorithms. These filters have not sacrificed 408 detection of known true positives. Further, sMACHETE assigns a statistical score that can be 409 used to prioritize fusions on the basis of statistical support, rather than the absolute read counts 410 supporting the fusion. Because of this, like any statistical test, by adjusting the threshold on 411 scoring, sMACHETE's discovery rate can be tuned to adjust the trade-off between sensitivity 412 and specificity, a feature unavailable in other algorithms but of potential scientific and clinical 413 utility (Hsieh et al., 2017) . 414
The sMACHETE algorithm improves detection of gene fusions that have been missed by 415 other algorithms' list of "high confidence" gene fusions. Analysis of these gene fusions uncovers 416 new cancer biology: evidence that gene fusions are more prevalent than previously thought in 417 high grade serous ovarian cancers, which lack explanatory oncogenic events, and perhaps are 418 a contributing driver of these cancers. Unlike other algorithms, sMACHETE finds an enrichment 419 of fusions in ovarian cancers that is consistent with the extremely high representation of TP53 420 mutations in these tumors. 421
Also, sMACHETE allows for the first rigorous and unbiased quantification of gene 422 fusions in solid tumors, and for tests of whether partners in gene fusions are present at greater 423 frequencies than due to chance. We find positive results, suggesting that gene fusions, even if 424 not recurrent themselves, are under selection by the tumor. Many fusion partners are detected 425 in more than one cancer type, which suggests that fusions may be lesions like point mutations, 426 present across tumors rather than tumor-defining, and suggests that by focusing on one tumor 427 type to detect recurrence, some important cancer biology is lost. Finally, it is also possible that 428 some fusions identified by sMACHETE, especially those that are local, could be germline 429 fusions, passengers or perhaps markers of genetic predisposition for cancer risk, topics we 430 intend to explore further in other work. 431
While sMACHETE has increased the accuracy of fusion detection, there are two obvious 432 extensions of this work. First, we could include all samples with known, clinically validated 433 fusions in sMACHETE's discovery set, enabling a strictly higher chance of discovering clinically 434 actionable events. This might further extend the list of potentially druggable fusions that 435 sMACHETE finds. Above, we described fusions between genes where one gene can be 436 drugged by existing therapies, including ERBB2 (HER2/neu). Further work with a clinical focus 437 is needed to determine the extent of potentially druggable fusions identified by sMACHETE, 438
including determinations of whether protein domains targeted by these drugs are included in the 439 fusion. Second, we have limited our analysis to fusion RNAs that occur at annotated exon-exon 440 boundaries; we believe that extending the statistical approaches used to discover gene fusions 441 may allow us to relax the requirement that gene fusions be detected at annotated exonic 442 sequences, without sacrificing the false positive rate. Doing so will provide a more powerful test 443 of whether genomic instability in cancers results in gene fusions that are a "passenger" of this 444 instability or that have currently under-appreciated functional and perhaps clinical importance. samples were designated and used as "testing" data (see Table 1 , Supplemental Table 2 , Fig. 3  455 and Supplemental File). As negative controls, we analyzed Illumina Human Body Map data sets 456 (Table 2 ) because, as described by the TCGA consortium, samples classified as "Solid Tissue 457
Normal" in the TCGA data sets are not consistently molecularly normal. In the discovery step, 458 due to cost limitations, we deeply sampled a subset of tumors; OV, GBM, and PAAD were 459 selected as diseases where early detection or new drug targets could have great impact, and 460 LAML was selected due to its extensively studied cytogenetics. 461
We constructed Sequence Bloom Trees (SBTs) for the Illumina Body Map data and for 462 the RNA-Seq data from each primary tumor from ten cancers with the TCGA dataset: LAML, 463 BRCA, cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), colon 464 adenocarcinoma (COAD), GBM, LUAD, OV, PAAD, PRAD, and SARC. We queried the SBT 465 with all fusions nominated in the discovery step that passed a statistical threshold 466 (Supplemental File). 467
We used the discovery set to generate a list of fusions passing MACHETE's statistical 468 bar (see Supplemental Table 3 , Fig. 1 ), including those fusions nominated by running 469 MACHETE on negative controls from the Body Map. We then queried all data sets for any 470 fusions found in any discovery set (see Fig. 1 ). We estimated the incidence of each fusion in 471 each sample type (each TCGA disease or Body Map) with SBTs. Next, we used standard 472 binomial confidence intervals to test for consistency of the rate that fusions were present in the 473 samples used in MACHETE's discovery step and the rate that they were found in the SBT. 474
Fusion sequences that were more prevalent across the entire data set than is statistically 475 compatible with the predicted prevalence from the discovery set were excluded from the final list 476 of fusions (see Fig. 1 ). 477
For intuition on why this step is important, consider the scheme in Figure 1: given an 478 exon-exon junction query sequence that could be generated by sequencing errors convolved 479 with gene homology or ligation artifacts, SBTs will not consider the alignment profile of all reads 480 aligning to this junction as MACHETE does, e.g., reads with errors or evidence of other artifacts, 481 because reads with mismatches with the query sequence are by definition censored by the 482 SBT. As a result, the SBT, like other algorithms, can have a high false positive rate due to: (a) 483 false positives intrinsic to the Bloom filters used in the SBT (Solomon and Kingsford, 2016); (b) 484 false positive identification of putative fusions due to events such as depicted in Figure 1 threshold in the discovery step, this artifact will be included as a query sequence, and the SBT 489 could detect it a high frequency because the statistical models employed by MACHETE are not 490 used by the SBT (see Fig. 1 ). Testing for the consistency of the rate of each sequence being 491 detected in the discovery set with its prevalence as estimated by SBTs controls for the multiple 492 testing bias described above (see below and Fig. 1) . reports, for each query sequence passing sMACHETE thresholds, were generated on a per-514 tumor basis, with a matrix of sample by fusion presence/absence statistics. Samples were 515 included if they were present in the SBT and in the MACHETE discovery set. COSMIC genes 516 and genes annotated as "involved in a kinase pathway" were defined by the annotations in the 517 cancer_gene_consensus.csv file downloaded from the COSMIC website and hg19 RefFlat 518 respectively, implying the chance that a randomly chosen gene would be be annotated with the 519 word 'kinase' or found in the COSMIC file is <3%. A gene was defined as having the term 520 "kinase" if its refFlat description included the word "kinase": 4590 out of 207194 distinct 521 transcript names with products annotated with the word kinase were identified in this refFlat file; 522 there are 595 COSMIC genes, out of all human genes. 
